Other small IDH inhibitors such as olutasidenib (FT-2102) are currently under investigation in phase I/II clinical trials for AML and myelodysplastic syndrome [202] as well as vorasidenib (AG-881), a pan inhibitor of both IDH1/2 enzymes, has been evaluated in glioma (NCT04164901) [199]. The gene discussed is IDH1; the disease is central nervous system cancer.